



Preferred
Research
Partners

Curriculum Vitae

Jessica Watson, CCRC

Research Affiliation

Preferred Research Partners, Inc.

11219 Financial Center Parkway,

Suite 320

Little Rock, AR 72211

(501) 553-9987 Phone

(501) 553-9986 Fax

Signature

Date

20 MAR 2017

Jessica Watson
jwtatson@preferredresearchpartners.com
501-553-9987 x.106

Office:

Paul E. Wylie, M.D., P.A. (Clinic Office)
11219 Financial Center Parkway, Suite 315
Little Rock, AR 72211
Phone: 501-661-9191 x.106 Fax: 501-661-1991

Arkansas Center for Sleep Medicine, PLLC (Polysomnography Lab)
11219 Financial Center Parkway, Suite 101
Little Rock, AR 72211
Phone: 501-661-9191 x.106 Fax: 501-661-1991

Preferred Research Partners, Inc.
11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
Phone: 501-553-9987 x.106 Fax: 501-553-9986

Education: Arkansas State University-Beebe
Pulaski Technical College
Associate of Applied Science in Business Technology with
emphasis in Legal Assistant
Graduation Date: May 2010
3.65 GPA

Work Experience: Preferred Research Partners, Inc., Little Rock, AR
August 2012 - present
Clinical Research Coordinator
Position involves conducting study visits & ensuring patient safety,
AE/SAE reporting, facilitating informed consent process, collection
of IRB correspondence, patient recruitment, CRF and source
documentation completion, laboratory collection and processing.

Research Experience:

- 2012: UCB, Restless Legs Syndrome in Adolescents – SP1004
- 2012: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102073
- 2012: Synergy Pharmaceuticals, Chronic Idiopathic Constipation – SP304-20210
- 2012: UCB, Restless Legs Syndrome in Adolescents – SP1005
- 2012: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102077

- 2012: Forest Research Institute, Hypertension – NAC-MD-01
- 2012: Ardea, Gout – RDEA594-301
- 2012: Orexigen, Obesity – NB-CVOT
- 2012: Novartis, High Triglycerides – CLCQ908C2201
- 2012: Furiex Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – 27018966IBS3001
- 2012: Lexicon Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – LX1033-1.201
- 2012: Tioga Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – ASMP3001
- 2012: Shionogi, Inc., Opioid Induced Constipation – 1107V9221
- 2012: Tsumura Pharmaceuticals, Crohn's Disease – TU100P2T2
- 2012: Coronado Biosciences, Crohn's Disease – CNDO-201-003
- 2012: Shire, GERD – SPD557-206
- 2012: UCB, Healthy Adult, Phase I – SP1031
- 2012: UCB, Restless Legs Syndrome – RL0003
- 2012: GSK, Restless Legs Syndrome – RXP114025
- 2013: Ardea BioSciences, Gout – RDEA594-306
- 2013: Dr. Reddy's Laboratories, Chronic Idiopathic Constipation – DRL-USG01-L/2012
- 2013: Purdue Pharma L.P., Chronic Low Back Pain & Opioid-Induced Constipation – ONU3705
- 2013: Cubist Pharmaceuticals, Opioid-induced Constipation – 5945-SOIC-12-05
- 2013: Cubist Pharmaceuticals, Opioid-induced Constipation – 5945-OIC-12-04
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000080
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000081
- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (OLE CIC) – SP304203-01
- 2013: Shionogi, Inc., Opioid Induced Constipation – 1315V9232
- 2013: Menarini, Diarrhea-Predominant Irritable Bowel Syndrome – NAK-07
- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (CIC3) – SP304203-00
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-003
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-004
- 2014: Eisai, Long-Term incidence of MACE events & conversion to Type II Diabetes Mellitus in Obese & Overweight Subjects with Cardiovascular Disease or Multiple CV Risk Factors – APD356-G000-401
- 2014: A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout – Takeda Development Center Americas, Inc. – FEB-XR_301

- 2014: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease – Salix Pharmaceuticals, Inc. – RECD3125
- 2014: A Randomized Double-Blind, Placebo Controlled, Flexible and Fixed Dose, Parallel Group Study of Extended-Release Lorazepam (EDG004) for the Treatment of Generalized Anxiety Disorder (GAD) – Edgemont Pharmaceuticals – EDG004-003
- 2014: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Assess The Effects Of TC-6499 on Gastric Emptying Time In Diabetic Subjects with Gastroparesis – Targacept – TC-6499-12-CLP-005
- 2015: Rhythm Pharmaceuticals, Diabetic Gastroparesis -RM-131-009
- 2015: Jazz Pharmaceuticals, Narcolepsy & Excessive Daytime Sleepiness - 14-002
- 2015: Jazz Pharmaceuticals, Obstructive Sleep Apnea & Excessive Daytime Sleepiness - 14-003
- 2015: Jazz Pharmaceuticals, Long-term extension study for Obstructive Sleep Apnea or Narcolepsy with Excessive Daytime Sleepiness - 14-005
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia -NBI-98854-1304 (KINECT3)
- 2015: Theravance, Diabetic or Idiopathic Gastroparesis -0099
- 2015: Synergy Pharmaceuticals, Inc., Irritable Bowel Syndrome-Constipation - SP304203-04
- 2015: Forest Research Institute, Inc., Irritable Bowel Syndrome-Constipation &/or Chronic Idiopathic Constipation -LIN-MD-10
- 2015: Edgemont Pharmaceuticals, Generalized Anxiety Disorder -EDG004-003
- 2015: Janssen Research & Development, Treatment-resistant Depression - ESKETINTRD3001 (TRANSFORM-I)
- 2015: Janssen Research & Development, Treatment-resistant Depression - ESKETINTRD3003 (SUSTAIN- I)
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia -NBI-98854-1402 (KINECT4)
- 2015: Naurex Inc., Major Depressive Disorder -NRX1074-C-202
- 2015: Gilead, Ulcerative Colitis -GS-US-326-1100
- 2015: Sunovion Pharmaceuticals, Adult Attention Deficit Hyperactivity Disorder (ADHD) - SEP360-301
- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis - 000174
- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis - 000175

- 2016: Conatus Pharmaceuticals, Non-alcoholic Steatohepatitis (NASH) - IDN-6556-12
- 2016: Synergy Pharmaceuticals, Irritable Bowel Syndrome with Constipation (IBS-C) - 'SP304203-06
- 2016: Janssen Research & Development, Treatment-resistant Depression - ESKETINTRD3008
- 2016: Eisai Pharmaceuticals, Elderly Insomnia -E2006-G000-304
- 2016: Luitpold Pharmaceuticals, Inc., Restless Legs Syndrome - 1VIT14037
- 2016: Braintree Laboratories, Chronic Constipation -BLI400-302
- 2016: Braintree Laboratories, Opioid Induced Constipation -BLI801-203

Training Documentation:

March 2017: Stericycle DOT Training

February 2017: Stericycle Biohazardous Waste Training

February 2017: Stericycle Steri-Safe: BBP Training

January 2017: CITI program
Human Subjects Research Basics

January 2017: National Institutes of Health web-based training on "Protecting Human Research Participants"

September 2016: American Red Cross, Adult and Pediatric First Aid/CPR/AED

January 2016: IATA Training

April 2015: CITI Program
Human Subjects Research Basics

September 2014: IATA training

July 2014: National Institutes of Health web-based training on "Protecting Human Research Participants"

March 2014: Stericycle Biohazardous Waste Training

March 2014: Stericycle DOT Hazardous Materials Training

October 2013: Stericycle Blood Borne Pathogen Training

September 2012: National Institutes of Health web-based training on "Protecting Human Research Participants"

September 2012: IATA training

September 2012: GCP Manual/Code of Federal Regulations Review
Phlebotomy Training
Informed Consent Training
Vital Signs Training
EKG Training
Coordinator Training
Job Shadowing
Blood Borne Pathogen Training
CRF Training
SOP Review
Lab Processing Training
HIPAA Training